UNSPSC 51362501: Amperozide

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C23H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M2W3TAG39, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-n-ethyl-1-piperazinecarboxamide but generally known as amperozide, which bears US NIH Compound Identifier 73333. Amperozide most often comes in base and hydrochloride forms. European Medicines Agency schedules Amperozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05483MIG.

UNSPSC 51362501 Amperozide is a Commodity code, but the recent state and local opportunity tagged under it involves procurement of naloxone and drug deactivation systems rather than the pharmaceutical compound itself—a significant scope mismatch. Seminole County, Florida released an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building. This represents acquisition of emergency medical supplies and harm-reduction equipment for community health initiatives, a materially different product class than amperozide. The county requires electronic bid submission through its e-Procurement Portal, with shipping and delivery costs included in vendor proposals; the contract carries a two-year initial term with a one-year renewal option and includes standard compliance requirements such as drug-free workplace certification, E-Verify verification, and specified insurance coverage.

The code shows minimal recent activity with only one documented opportunity. Seminole County, a Florida county health department, is the sole identified issuing body in the recent-opportunities block. The IFB closing date was July 26, 2023 (though the opportunity was reposted in June 2026), with questions due July 21, 2023. Geographic activity is limited to Florida based on available records. The mismatch between the Commodity code's nominal scope and the actual procurement suggests either a tagging error in the underlying opportunity or a category that sees little relevant state and local sourcing activity for the pharmaceutical itself. Business development professionals should verify whether amperozide procurement appears under alternative codes or whether this particular Commodity sees material demand from state and local health departments, correctional facilities, or other public agencies before resource allocation.